Tci Gene (ROCO:6879) Gross-Profit-to-Asset % : 16.35% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Tci Gene Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Tci Gene's annualized Gross Profit for the quarter that ended in Dec. 2023 was NT$193.7 Mil. Tci Gene's average Total Assets over the quarter that ended in Dec. 2023 was NT$1,184.4 Mil. Therefore, Tci Gene's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 16.35%.

Tci Gene Gross-Profit-to-Asset % Historical Data

The historical data trend for Tci Gene's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene Gross-Profit-to-Asset % Chart

Tci Gene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

54.96

42.85

54.69

28.24

14.99

Tci Gene Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				68.60	32.74	16.90	13.15	16.35

Competitive Comparison of Tci Gene's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Tci Gene's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tci Gene's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tci Gene's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Tci Gene's Gross-Profit-to-Asset % falls into.

Tci Gene Gross-Profit-to-Asset % Calculation

Tci Gene's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	174.617	/	( (1163.329	+	1165.94)	/ 2 )
	=	174.617	/	1164.6345
	=	14.99 %

Tci Gene's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	193.7	/	( (1202.864	+	1165.94)	/ 2 )
	=	193.7	/	1184.402
	=	16.35 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Tci Gene Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Tci Gene's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tci Gene (ROCO:6879) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN

Website

https://www.genext.me

Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines